Drugs / NEX-20A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05643248 | Nov 2022 → Sep 2023 | plasma cell myeloma | Nanexa AB | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-11-14 | Nanexa AB | Results Nanexa presented Health Economical data at international conference nanexa.com ↗
In short, our study shows that patients’ adherence to their drug treatment against multiple myeloma might be suboptimal. |
| 2023-10-05 | Nanexa AB | Results Nanexa completes clinical phase I study with NEX-20 nanexa.com ↗
Nanexa AB today announces that the phase I study NEX-20-01 has been completed with the last follow-up visits for the last of the three dose levels studied. |
| 2023-08-22 | Nanexa AB | Results Nanexa obtains pharmacokinetic data from the NEX-20 Phase 1 study confirming controlled release of lenalidomide nanexa.com ↗
Nanexa AB today announced that pharmacokinetic data from the Phase 1 study NEX-20-01 confirmed a release profile of lenalidomide in different doses up to 21 days. |
| 2022-11-14 | Nanexa AB | Regulatory Nanexa receives approval to start clinical trial with NEX-20 nanexa.com ↗
Nanexa AB (publ) today announced that it has received approval from the Swedish Medical Products Agency to initiate a clinical trial of its drug candidate NEX-20 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-14 | Nanexa AB | Nanexa presented Health Economical data at international conference nanexa.com ↗ |
| 2023-10-05 | Nanexa AB | Nanexa completes clinical phase I study with NEX-20 nanexa.com ↗ |
| 2023-08-22 | Nanexa AB | Nanexa obtains pharmacokinetic data from the NEX-20 Phase 1 study confirming controlled release of lenalidomide nanexa.com ↗ |
| 2022-11-14 | Nanexa AB | Nanexa receives approval to start clinical trial with NEX-20 nanexa.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEX-20A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05643248 ↗ |
| Known as | lenalidomide | “This is a single-centre, single ascending dose (SAD) pilot study designed to evaluate the safety, tolerability, including local tolerability, and pharmacokinetics (PK) of...” NCT05643248 ↗ |
| Route | Subcutaneous | “Subcutaneous prolonged-release injection” NCT05643248 ↗ |